Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06733688 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT06733688 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 36 participants.
The verdict
NCT06733688, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference in the absorption and elimination of different oral formulations from the healthy person's body.
Interventions
- DRUG Tedizolid Phosphate Oral Formulation 1 (Reference)
- DRUG Tedizolid Phosphate Oral Formulation 2 (Test)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-03-23 |
| Est. Completion | 2022-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06733688
The ClinicalTrials.gov registry entry for NCT06733688 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tedizolid Phosphate Oral Formulation 1 (Reference) is the first listed.
NCT06733688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06733688 about?
NCT06733688 is a clinical study titled "A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)". The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference in the absorption and elimination of different oral formulations from the healthy person's body.
What is the current status of trial NCT06733688?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-03-23. Estimated completion is 2022-04-15.
What interventions are being tested in trial NCT06733688?
The interventions under investigation include: Tedizolid Phosphate Oral Formulation 1 (Reference) (DRUG), Tedizolid Phosphate Oral Formulation 2 (Test) (DRUG).
Who is sponsoring clinical trial NCT06733688?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.